Cancer research communications
Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo.
Jasmin Traichel, Ariane Metzger, Maria Walz, Reinhild Feuerstein, Nadine Wohlfeil, Patrick Metzger, Lisa Marx, Célia Asdih, Agnes Lindenthal, Alina Seger, Jule Schrimpf, Luigi L Nardella, Silke Kowar, Ian J Frew, Sebastian Halbach
Published: 202610.1158/2767-9764.CRC-25-0599
Abstract
Combining anti-EGFR antibodies with BRAF/MEK/ERK-pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer (CRC). Nevertheless, responses of these poor-prognostic cancers are short-lived and heterogeneous, thereby highlight…
Preview only. Read the full abstract at the source